Mutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience

Simple item page
dc.contributor.authorCordova-Delgado, Miguel
dc.contributor.authorPinto, Mauricio P.
dc.contributor.authorRegonesi, Carlos
dc.contributor.authorCereceda, Luis
dc.contributor.authorReyes, Jose Miguel
dc.contributor.authorItriago, Laura
dc.contributor.authorMajlis, Alejandro
dc.contributor.authorRodriguez, Pablo
dc.contributor.authorFassler, Andre
dc.contributor.authorMahave, Mauricio
dc.contributor.authorLeon, Maria Elisa
dc.contributor.authorGallardo, Jorge
dc.contributor.authorRodriguez, Maria Paz Z.
dc.contributor.authorBerkovits, Alejandro
dc.contributor.authorManque, Patricio
dc.contributor.authorRios, Juvenal A.
dc.contributor.authorGarcia-Bloj, Benjamin
dc.contributor.authorGarrido, Marcelo
dc.date.accessioned2025-01-20T21:11:46Z
dc.date.available2025-01-20T21:11:46Z
dc.date.issued2022
dc.description.abstractMajor advances in sequencing technologies and targeted therapies have accelerated the incorporation of oncology into the era of precision medicine and "biomarker-driven" treatments. However, the impact of this approach on the everyday clinic has yet to be determined. Most precision oncology reports are based on developed countries and usually involve metastatic, hard-to-treat or incurable cancer patients. Moreover, in many cases race and ethnicity in these studies is commonly unreported and real-world evidence in this topic is scarce. Herein, we report data from a total of 202 Chilean advanced stage refractory cancer patients. Retrospectively, we collected patient data from NGS tests and IHC in order to determine the proportion of patients that would benefit from targeted treatments. Overall >20 tumor types were included in our cohort and 37% of patients (n = 74) displayed potentially actionable alterations, including on-label, off-label and immune checkpoint inhibitor recommendations. Our findings were in-line with previous reports such as the cancer genome atlas (TCGA). To our knowledge, this is the first report of its kind in Latin America delivering real-world evidence to estimate the percentage of refractory tumor patients that might benefit from precision oncology. Although this approach is still in its infancy in Chile, we strongly encourage the implementation of mutational tumor boards in our country in order to provide more therapeutic options for advanced stage refractory patients.
dc.fuente.origenWOS
dc.identifier.doi10.3390/jpm12020195
dc.identifier.eissn2075-4426
dc.identifier.urihttps://doi.org/10.3390/jpm12020195
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/93633
dc.identifier.wosidWOS:000769737600001
dc.issue.numero2
dc.language.isoen
dc.revistaJournal of personalized medicine
dc.rightsacceso restringido
dc.subjectprecision oncology
dc.subjectNext-Generation Sequencing
dc.subjecton-label
dc.subjectoff-label
dc.subjecttherapy
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleMutational Landscape and Actionable Target Rates on Advanced Stage Refractory Cancer Patients: A Multicenter Chilean Experience
dc.typeartículo
dc.volumen12
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas